Kincell Bio News and Resources

Kincell Bio, a cell therapy contract development and manufacturing organisation (CDMO), has entered into a new multi-year agreement with a clinical-stage cell therapy company. The partnership will focus on producing patient-specific batches of clinical-grade cell therapy products at Kincell’s facility

Kincell Bio has announced a new multi-year partnership with a leading biotechnology company for the production of early-phase clinical material of an allogeneic cell therapy product. The contract follows Kincell Bio’s acquisition of a GMP-ready facility in April 2024. This